Louisiana Welder Survives Rare Case of “Welder’s Anthrax” with Antitoxin Treatment
January 5, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Acova
Synonyms :
argatroban
Class :
Cardiovascular, Anticoagulants; Hematologic, Anticoagulants; Thrombin Inhibitors
Dosage Forms & Strengths
Solution for injection
100mg/mL
Injection ready-to-use
250mg/2.5mL of 0.9% NaCl
125mg/125mL of 0.9% NaCl
50mg/50mL of 0.9% NaCl
Safety and efficacy not established
Refer to the adult dosing regimen
may enhance the effect of each other when combined
piperacillin will increase the effectiveness of argatroban by anticoagulation.
when both drugs are combined, there may be an increased effect of argatroban by anticoagulation
when both drugs are combined, there may be an increased effect of argatroban by anticoagulation
when both drugs are combined, there may be an increased effect of argatroban by anticoagulation
anticoagulants increase the effect of anticoagulation of rivaroxaban
it increases the effect of anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased thrombogenic effect when combined with anti- coagulant inhibitor complex
synthetic conjugated estrogens, b
the activity of argatroban may be decreased due to pharmacodynamic antagonism
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
may increase the anticoagulation when combined with ginkgo biloba
It may diminish the effects when combined with estradiol valerate by pharmacodynamic antagonism
The potential for bleeding risk or its seriousness may elevate when argatroban is used together with troxerutin
When argatroban is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
ardeparin: it may decrease the therapeutic efficacy of etynodiol
chlorotrianisene may lower the anticoagulant activities of argatroban
the argatroban effects of action increases.
may diminish therapeutic effects of argatroban
when both drugs are combined, there may be an increased risk or severity of adverse effects
the unspecific interaction mechanism of gemcitabine increases the efficacy of argatroban
the effect of argatroban is increased by fluorouracil with the help of an unspecific interaction mechanism
may increase the anti-coagulant effect of antiplatelet agents
may enhance the anticoagulant effect
may increase the anticoagulant effect of pentosan polysulfate sodium
anticoagulation is increased by alfalfa and decreased by mistletoe. The interaction's effect is unclear; exercise caution
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
The anticoagulant effects of ancord may be enhanced when administered concomitantly with other anticoagulants
the chances for the occurrence of hemorrhage can be elevated when indalpine is combined with argatroban
when both drugs are combined, there may be an increase in the anticoagulant effect
miconazole nitrate/hydrocortisone
the activity of oral anticoagulants may be increased
it may increase the anticoagulant effect
demeclocycline may enhance the therapeutic effects of argatoban
doxycycline may enhance the therapeutic effects of argatoban
Actions and spectrum:
argatroban is a direct thrombin inhibitor that acts by binding to the active site of thrombin and prevents conversion of fibrinogen to fibrin. It is used as an anticoagulant in patients with or at risk of developing heparin-induced thrombocytopenia (HIT), a serious immune-mediated complication of heparin therapy.
argatroban has a short half-life and is primarily eliminated through hepatic metabolism. The spectrum of argatroban is limited to its action on thrombin and does not affect other coagulation factors or platelet function.
Frequency defined
1-10%
Angina (1.8%)
Coronary thrombosis (1.8%)
Coronary artery bleeding (1.8%)
GI bleeding (1-2%)
Brachial bleeding (2%)
Hemoptysis (3%)
Cough (3%)
Nephrotoxicity (3%)
Atrial fibrillation (3%)
Myocardial infarction (3.5%)
Chest pain (1-15%)
Intracranial bleeding (1-4%)
Vomiting (2.6-4%)
Infection (4%)
Bradyarrhythmia (4.5%)
Nausea (5%)
Pain (5%)
Ventricular tachycardia (5%)
Groin bleeding (5%)
UTI (5%)
Sepsis (6%)
Diarrhea (6%)
Cardiac arrest (6%)
Fever (7%)
decrease in Hemoglobin and hematocrit (10%)
Dyspnea (8%)
Hypotension (7-10%)
>10%
Hematuria (12%)
GI bleeding (14%)
Frequency not defined
Pulmonary edema
Minor hematuria
Contraindication/Caution:
Contraindication:
Caution:
Comorbidities:
argatroban is a thrombin inhibitor used as an anticoagulant, in patients with heparin-induced thrombocytopenia (HIT) and for prophylaxis or treatment of thrombosis associated with HIT. However, as with any anticoagulant, caution should be exercised in patients with a history of bleeding disorders, recent surgery, severe hypertension, or hepatic or renal impairment. In addition, argatroban should not be used in patients with a known hypersensitivity to argatroban or its components.
Pregnancy consideration: Pregnancy Category B
Lactation: It is not known if argatroban passes into breast milk
Pregnancy category:
Pharmacology:
argatroban is a direct thrombin inhibitor that binds to thrombin and inhibits its function. It is a small molecule that is structurally like arginine and has a molecular weight of 508 Da. argatroban is primarily metabolized by the liver and excreted in the feces. It has a half-life of 50-65 minutes and is administered intravenously. argatroban is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and for prophylaxis and treatment of thrombosis in patients with a history of HIT.
Pharmacodynamics:
argatroban is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, thus inhibiting its activity. It does not require cofactors such as antithrombin III to exert its anticoagulant effects. argatroban prevents fibrin formation and clot formation, thus preventing thrombus formation. Its onset of action is immediate, and its effect is dose dependent. argatroban has no effect on platelet function, and it does not affect the PT/INR (prothrombin time/international normalized ratio) test results.
Pharmacokinetics:
Absorption
argatroban has low oral bioavailability and is administered intravenously.
Distribution
The protein binding of argatroban is approximately 54%.
Metabolism
argatroban is primarily metabolized by the liver, with a half-life of about 40-50 minutes. It is metabolized by hydroxylation and then conjugated with glucuronic acid to form inactive metabolites.
Elimination and excretion
The excretion of argatroban is primarily via fecal route. About 65% of the administered dose is excreted in the feces, and approximately 22% is excreted in the urine.
Administration:
argatroban is available as an intravenous (IV) injection and is administered by a healthcare professional in a hospital setting. The duration and dosage of treatment depend on the patient’s condition, age, and other factors. argatroban should be given as a continuous IV infusion over a period of 48 to 72 hours.
The initial infusion rate is based on the patient’s baseline activated partial thromboplastin time (aPTT) and weight, and subsequent doses are adjusted based on the patient’s response to treatment and laboratory values. After 48 to 72 hours of IV infusion, argatroban therapy can be continued with subcutaneous injections.
Patient information leaflet
Generic Name: argatroban
Pronounced: (ar-ga-troh-ban)
Why do we use argatroban?
argatroban is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT). It is also used for prophylaxis or treatment of thrombosis in patients with thrombosis-associated disorder (TAD) undergoing percutaneous coronary intervention (PCI) or who are not candidates for heparin. Additionally, argatroban is used in patients with acute ischemic stroke (AIS) to prevent further thromboembolism.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
